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Production of immun0reactive (it-) endothelin-2 (ET-2) in renal adenoearcinoma cells, ACI IN, was reduced by transforming growth factor-fl, basic 
fibroblast growth factor, transforming growth factor-at and, most strikingly, by epidermal growth factor (EGF). These growth factors did not show 
such inhibitory effects on the secretion of ir-ET-I in ET-l-producing cells, indicating that the production of ET-2 and ET-I is regulated ifferently 
by the growth factors. EGF  specifically reduced the sacra :on of not only ir-ET-2 but also ir-big ET-2 with only a small decrease in total protein 
synthesis. Northern blot analysis indicated that EGF controls the ET-2-production at the transcription levels of  ET-2 gene. 
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1. INTRODUCTION 
Endothelins (ETs), namely ET-I, ET-2, and ET-3, are 
a recentiy discovered family of peptides consisting of  21 
amino acid residues and two disulfide bonds [1,2]. 
Among them, ET-1, originally identified as an endothe- 
lium-derived contracting factor, has attracted much at- 
tention from the viewpoint of its potent and long-lasting 
vasoconstriction a d pressor activity. ET-I showed var- 
ious pharmacological ctivities in both cardiovascular 
and non-cardiovascular tissues [3]. Especially, ET-I is 
thought o play important roles in the kidney in the 
control of mesangial cell function, glomerular filtration 
rate, renal vascular tone [4] and ion transport/water 
permeability [5]. 
ET-2 differs from ET-i in two amino acid residues in 
humans and is characterized as the most hydrophobia 
endothelin [2]. Immunoreactive (ir-) ET-2 was found in 
,I..~ ;..,t~otl,-,, gad ~r~lr~n in r~t~ [~1 In humans, renal 
medulla is also an organ expressing high levels of 
mRNAs of prepro-ET-2, as well as prepro-ET-I [7]. 
Since ET-2 is as potent as ET-1 in vasoconstricting 
activity, and shares two classes of receptors with ET-I 
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[8.9], it is of particular interest o examine how the 
functions and production of these ndothelins are regu- 
lated, especially in the kidney. However, there have been 
few reports concerning physiologic and pathophys- 
iologic roles of  ET-2 and regulation of  its synthesis. 
Recently, a human cell line derived from renal adeno- 
carcinoma, ACHN,  was found to produce a large 
amount of ET-2 but not ET-I [10]. The discovery of  the 
ET-2-produeing cells enabled us to isolate eDNAs 
coding for human prepro-ET-2 [11] and investigate the 
regulation of ET-2 biosynthesis. 
It has been reported that the production of ir-ET-! 
is enhanced by transforming rowth factor (TGF)-fl in 
PAE (porcine aortic endothelial cells) [1,12] and HepG- 
2 (human hepatocellular carcinoma cells) [12]. In the 
present study, we investigated the effects of various 
growth factors on the secretion of ET-2 in ACHN, and 
compared %ose with the secretion of  ET-! in MDCK 
(canine normal kidney cells) [12,13], HepG-2 and PAE. 
These studies showed that epidermal growth t~actor 
(EGF), a growth factor expressed abundantly in the 
kidney, markedly inhibited ET-2 production in ACHN. 
2. MATERIALS AND METHODS 
2.1. Materials 
Basic-fibroblast growth factor (bFGF), EGF. insulin, nerve growth 
factor (NI3F), TGF-a and TGF.fl wore obtained from Wako Pure 
Chem. (Osaka, Japan); insulin-like growth factor(IGF).! and platelet- 
derived growth factor (PDGF) from B0ehringer (Mannheim, Ger- 
many); I~3F-II from Bachem Inc. (Torrance, USA); bovine serum 
albtlmin (lISA) from gigma Chem. Co. (St. Louis, LISA); ET-I, ET-2 
and big ET-2 from Peptide Institute (Osaka, Japan); [~l-l]lcucine from 
Amersham (Buckinghamshire, England). 
Published by Elsevier Science Publishers B. V. i 7 
Volume 295, number 1,2,3 FEBS LETTERS December 1991 
2.2. Cells and culture condithms 
Ir-ET-I or ir-ET-2 secreted in PAE, MDCK, HepG-2 or ACI-IN 
were previously characterized [I 0,12.13]. PAE was prepared according 
to the methods of Neieh et a1.[14]. ACHN, MDCK and HepG-2 were 
obtained from American Type Culture Collection. PAE was cultured 
in Dulbeceo's modified Eagle's medium (DMEM)supplemented with 
10% heat-inactivated f tal call'serum (FCS), penicillin (100 U/ml), and 
streptomycin (50 ,ug/ml) [12]. ACHN. MDCK, and HepG-2 were 
cultured in minimum essential medium supplemented with non-essen- 
tial amino acids (MEM-NEAA), FCS and antibiotics, as given above 
[12]. 
The cells were grown to confluency in 24-well plates and washed 
with I ml of serum-free DMEM. Then, the medium was replaced with 
DMEM containing various factors to be tested and 0.1% of BSA. 
After incubation for 24 h, the culture medium was harvested and 
subjected to the EIAs. 
2.3. Detection of ET-I. ET.2 and big ET-2 
A sandwich-type EIA for ET-I [13,15] was used to measure ET-I 
and ET-2 in the culture medium. The EIA detects ET-2 as well as ET-I 
(detection limit, 0.2 pg/well) without he erossreaetion with ET-3 and 
big ETs. A sandwich-EIA for big ET-2 consists of two monoclonal 
antibodies, AwETN40 [15] ,rod bET-20 [16], directed against he N- 
terminal portion of ET-2 and C-terminal portion of big ET-2(22-37), 
respectively. The EIA specifically detects as little as 0.4 pgtwell of big 
ET-2 [16]. These EIAs were carried out in the same manner described 
previously [15]. 
2.4. [)H]l,,cine hzcorporation 
ACItN cells were grown confluently in 96-well plates and the cul- 
ture medium was replaced with 200 ,u! of fresh serum-free MEM- 
NEAA containing 5 and 20 ng/ml of EGF. After 3 h exposure of EGF 
to the cells, the medium was replaced either with leucine-free RPMI- 
1640 containing the same concentrations of EGF and 0.25 ,uCi/well 
of [~H]leucine or with fresh serum free MEM-NEAA containing the 
same concentrations of EGF. After another incubation for 3 h, the 
cells incubated in the medium containing [-'H]leucine were collected on 
the filter and their radioactivity was measured with a scintillation 
counter (LS 5801, Beckman Instruments Inc., Palo Alto, CA). Sim.i. 
larly, the culture media of tl:e cells incubated in the fresh serum-free 
MEM-NEAA were subjected to the EIA for ET-2. 
2.5. NorthenJ blot analysis 
ACHN cells were pro-incubated for 1 day with serum-fr.~e MEM 
containing 0.2% BSA and then incubated for 4 h in MEM with or 
ffithout 20 n~ml EGF. A p01y(A) ÷RNA was prepared using mRNA 
isolation kit (Invitrogen. San Diego, CA). Northern blot analysis was 
carried out according to the methods of Thomas etal. [17]. A 10/.tg 
portion of poly(A)" RNA separated by e!eetrophoresis on 1.2% ago- 
rose gel was transferred to the nitrocellulose filter (Schleieher & 
Schnell, Dassel, Germany) and hybridized in the buffer containing 
50% formamide at 42°C for 16 h with a-'P-labelled human ET-2 eDNA, 
pH ET-2 (k), cloned in advance from ACHN [I 1]. After hybridization, 
the filter was washed with 2×SSC (0.3 M NaCI, 30 mM trisodium 
citrate) and 0.1% SDS at 52°C. 
3. RESULTS 
3.1. Effects o f  t,arious factvrs on the secretion o f  ir-ET-I 
and h'-ET-2 
ACHN,  MDCK,  HepG-2  and PAE were used to in- 
vestigate the regulatory effects o f  var ious  growth  fac- 
tors on  the secretion o f i r -ET - !  or  i r -ET -2  (Tab le  I). The  
basal  level o f  i r -ET-2 in the cu l ture med ium o f  ACHN 
was approx imate ly  400 pg/106 cel ls /day and  those o f  ir- 
ET- I  in the cu l ture media  o f  PAE,  MDCK.  and  HepG-2  
were 2600, 350 and 50 pg/106 cel ls/day,  respectively. 
Secret ion o f  i r -ET-2 in ACHN was inh ib i ted by TGF-  
fl, bFGF ,  TGF- :x  and,  most  str ik ingly,  by EGF  at con-  
cent ra t ions  less than 10 -a M,  whereas  insu l in ,  IGF - I ,  
IGF - I I ,  PDGF and NGF did not  show any  inh ib i to ry  
effects on  the secretion of  i r -ET-2 in ACHN at concen-  
t rat ions  of  i0  -B M or more.  Secret io, l  o f  i r -ET-1 was 
enhanced by var ious growth  factors in HepG-2 ,  and  
sl ightly enhanced by TGF- f l  and  PDGF in MDCK and 
PAE.  EGF  (3 x 10 -9 M,  20 ng/ml)  on ly  sl ightly affected 
the product ion  of  ir-ET-1 in MDCK and  PAE.  bFGF 
and T(3F-¢~ have a tendency  s imi lar  to EGF  in the 
regu lat ion  o f  the synthesis o f  ET-1 and  ET-2.  
3.2. Effects o f  EGF on the secretion of  ir-ET-2 and h'-big 
ET-2 #~ A CHN 
Fig. 1 shows the t ime-course o f  the i r -ET -2  release 
into the med ium.  The inh ib i t ion  o f  i r -ET-2  product ion  
was s igni f icant (P<0.001) at 5 h after  the add i t ion  of  
Table I 
Effects of various growth factors on the secretion of ir-ETs in ACHN, MDCK, HepG-2 and PAE 
• l i t&  e.m,,,~ Co:leentrat.on ~..,) it'-ET-2: ir-El'-l; 
ACHN (%): MDCK (%) HepG-2 (%) PAE (%) 
Control 100 I00 100 100 
EGF 3x10 ~ 15 87 220 110 
TG F-,', 4x 109 21 89 290 nt-' 
TGF-fl 2xl 0 ,u 46 140 670 150 
bFOF 3x10 -:° 22 8l 150 110 
Insulin Ix l0- '  130 II0 nt 88 
IGF-I lx l0 -7 140 100 nt 100 
IGF-Ii Ixl0 "7 95 86 nL 79 
PDGF I×10 -H I l0 190 330 140 
NGF lxl0 -s I l0 130 180 79 
Ir-ETs in the culture medium were measured by a s:mdwich.EIA for ET-I fully crossreactive with ET-2. 
2 Results are expressed in % of control. 
-' not tested. 
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Fig. I. Time-course of the inhibiting effects of EGF on the ir-ET-2 
secretion in ACHN. The ACHN cells were cultured without (O) or 
with EGF (A, 0.2 ng/ml; ®, 2 ng/ml; B, 20 ngJml) and aliquots of the 
culture medium were subjected to the sandwich-EtA for ET-I(ET-2). 
Each point represents he mean _+ SEM (n=6). Asterisks how statisti- 
cally significant differences from control (*P < 0.05, **P < 0.001). 
EGF at the concentration of 0.2 ng/ml. EGF at the 
concentrations 2 and 20 ng/ml almost completely in- 
hibited the secretion of ir-ET-2. 
By the use of an EIA for big ET-2, it was found that 
ACHN secreted 200 p,g/106 ceils/day of ir-big ET-2 con- 
comitantly with ir-ET-2. As shown in Fig. 2, EGF re- 
duced the secretion of Jr-big ET-2 along with ir-ET-2 in 
a dose- and time-dependent manner. The addition of 2 
and 20 ngJml of EGF similarly blocked the secretion of 
ir-big ET-2 in ACHN. 
3.3. Effects of EGF on the proteh2 synthesis hi A CHN 
[3H]Leucine incorporation i to ACHN was investiga- 
ted in the presence and absence of EGF (Fig. 3). After 
3 h exposure to 5 and 20 ng/ml of EGF, the ir-ET-2 
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Fig. 2. Time.course of the inhibiting effects of EGF on the ir-big ET-2 
secretion. The ACHN cells were cultured without (0) or with EGF (&, 
0.2 ng/ml; e, 2 ng/ml; II, 20 ng/ml). The culture medium was assayed 
for it.big ET-2 by the sandwieh-EIA. Asterisks how statistically sig. 
nifieant differences from control (*P < 0.005, **P < 0.001), Details 
are shown in Fig, i, 
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Fig. 3. Effect of EGF on the [~H]leucine incorporation thatched bars) 
and secretion of ir-ET-2 (open bars) in ACHN cells. Each point repre- 
sents the mean + SEM (n=6). 
production during another 3 h incubation was reduced 
to 20-25% of the basal level with only a small decrease 
in the incorporation of [3H]leucine into the cells. These 
results indicate that the inhibition of ir-ET-2 secretion 
by EGF was not due to the decrease in the total protein 
synthesis. 
3.4. Effects of EGF on ET-2 gene transcription in 
ACHN 
To examine the effects of EGF on the expression 
levels of the ET-2 gene, poly(A) + RNA derived from 
ACHN cells cultured with or without EGF was analyz- 
ed by Northern blotting using 3'-P-labelled human ET- 
2 eDNA as a probe. As shown in Fig. 4, a single band 
corresponding to the ET-2 mRNA was observed at the 
position of 1.4 kbase. The band was obscured in the 
9.49 
7.96 
4A0,- 
2.37- 
i 
1.35 ,- 
1 2 
Fig. 4. Northern blot analysis of the poly(A)" RNA derived from 
ACHN cells cultured for 4 h with (lanu 2) or without (lane I ) 20 ng/ml 
EGF. The arrow indicates the size of ET-2 gene transcripts (1.4 kb). 
Molecular size markers are shown on the left. 
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experiment using RNA of the cells treated with 20 ng/ml 
of EGF, indicating that EGF decreased tb" transcrip- 
tion of ET-2 gone. 
4. DISCUSSION 
The present study has shown that the production of 
ET-I and ET-2 is regulated differently by various 
growth factors. TGF-fl enhanced the secretion of ir-ET- 
1 in MDCK and other cells as described previously 
[1,12], but reduced ir-ET-2 secretion in ACHN, indicat- 
ing that the production of ET-1 and ET-2 is regulated 
in the opposite direction by TGF-fl. EGF strongly in- 
hibited ET-2 secretion in ACHN, but only slightly af- 
fected the ir-ET-I secretion in MDCK and endothelial 
cells, and enhanced ir-ET-I secretion in HepG-2. TGF- 
t~, another ligand for the EGF receptor [18], and bFGF 
also markedly decreased ir-ET-2 secretion in ACHN. 
The reduction of the ET-2 secretion by EGF was ob- 
served with only a small decrease in total protein syn- 
thesis, indicating that the reduction is specific to ET-2. 
Northern blot analysis howed that EGF controlled the 
ET-2 production at the transcription levels of prepro- 
ET-2 gone. This result was consistent with the fact that 
big ET-2 levels also decreased along with those of ET-2. 
EGF positively and negatively regulates the tran- 
scription of various genes. Enhancement of the tran- 
scription of proto-oncogenes such as c-jun, c-fos and 
e-myc was observed in the mitogenic stimulation of cul- 
tured rat and mouse fibroblasts by EGF [19,20]. On the 
other hand, EGF decreases mRNA levels of inhibin in 
cultured rat granulosa cells [21]. Similar to the observa- 
tion that the ET-2 secretion was inhibited by bFGF, the 
transcription of the inhibin gene was also repressed by 
bFGF [21]. Since the EGF and bFGF receptors have 
cytoplasmic tyrosine domains [22,23], signal transdue- 
tions triggered by tyrosine kinase may participate in the 
regulation of the transcriptions of ET-2 and inhibin 
genes by EGF, TGF-ct and bFGF. 
The renal medulla is an organ expressing relatively 
high levels of prepro-ET-2 mRNA in humans [7]. In 
addition, ACHN was established from human renal 
adenocarcinoma which arises from the renal tubular 
epithelial cells [24]. Although the localization of ET-2 
in the kidney has not yet been clarified in detail, the 
close relation of ET-2 with the renal tissues is also sug- 
gested by the fact that a relatively high amount of ir-big 
ET-2 but not ir-ET-1 or ir-big-ET-I is found in human 
urine compared to plasma (unpublished observation). 
Various growth factors have been thought to play 
roles in the kidney [25]. Although EGF is detectable in
many adult mammalian tissues uch as mammary and 
salivary glands, one major site of production is the kid- 
ney [26,27]. In humans, intense immunostaining of EGF 
was observed in the renal medulla [27]. EGF is present 
abundantly in the kidney as the large precursor protein 
[26], which is thought o retain EGF-like biological ac- 
tivity [28]. Therefore, it may be possible that EGF or a 
large precursor form of EGF represses transcription of 
prepro-ET-2 gone at a physiological condition in the 
kidney. In addition, concerning pathological roles of 
EGF in the kidney, it was reported that renal prepro- 
EGF mRNA and urinary EGF secretion were reduced 
during cysplatin and ischemia-induced acute renal fail- 
ure~ m rats [29]. Interestingly, ET(s) appeared to be a 
deleterious mediator in drug- or ischemia-induced renal 
failures in rats [30,31]. Therefore, the inhibitory mecha- 
nism of the ET-2 gene expression by EGF might play 
a role in the prevention of overproduction of the poten- 
tially toxic peptide, ET-2, in the physiological condi- 
tions of the kidney. 
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